BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1021@pharmaconomics
DTSTAMP:20260707T051347Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:TSHA Phase 2 — TSHA-102
DESCRIPTION:Phase 2 trial results for TSHA-102 in Rett syndrome are due Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/d46409dex991.htm\n\nTrack it: https://www.pharmaconomics.com/e/1021
URL:https://www.pharmaconomics.com/e/1021
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:TSHA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR